About TearSolutions
TearSolutions is a company based in Charlottesville (United States) founded in 2013. TearSolutions has raised $44.07 million across 12 funding rounds from investors including Santen Pharmaceuticals, VTC Innovation Fund and Pharmstandard. TearSolutions offers products and services including Lacripep. TearSolutions operates in a competitive market with competitors including Remegen, Oyster Point Pharmaceuticals, Biophytis, Azura Ophthalmics and Retrotope, among others.
- Headquarter Charlottesville, United States
-
Sectors
Healthcare
-
Email
Locked
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$44.07 M (USD)
in 12 rounds
-
Latest Funding Round
$517 K (USD), Series B
Oct 29, 2025
-
Investors
Santen Pharmaceuticals
& 4 more
-
Employee Count
Not available
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of TearSolutions
TearSolutions offers a comprehensive portfolio of products and services, including Lacripep.
Topical treatment to restore tear film and heal ocular surfaces.
People of TearSolutions
Unlock access to complete
Unlock access to complete
Funding Insights of TearSolutions
TearSolutions has successfully raised a total of $44.07M across 12 strategic funding rounds. The most recent funding activity was a Series B round of $517 thousand completed in October 2025. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in TearSolutions
TearSolutions has secured backing from 5 investors, including venture fund and institutional investors. Prominent investors backing the company include Santen Pharmaceuticals, VTC Innovation Fund and Pharmstandard.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
-
|
Locked | Locked | Locked | |
|
VC firm investing in seed & early stage companies in the US
|
Locked | Locked | Locked | |
|
Early-stage VC firm funding companies in the US
|
Locked | Locked | Locked |
Investor details for TearSolutions
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by TearSolutions
Investment portfolio details for TearSolutions
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - TearSolutions
Detailed financials for TearSolutions
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Tearsolutions Comparisons
Peer comparison for TearSolutions
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of TearSolutions
TearSolutions operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Remegen, Oyster Point Pharmaceuticals, Biophytis, Azura Ophthalmics and Retrotope, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Therapies for cancer, autoimmune, and eye diseases are developed.
|
|
| Locked | Locked | Locked |
Gene therapies for ophthalmological diseases are developed.
|
|
| Locked | Locked | Locked |
Drugs for neuromuscular and age-related diseases are developed.
|
|
| Locked | Locked | Locked |
Developing therapies for meibomian gland dysfunction
|
|
| Locked | Locked | Locked |
Therapeutics for neurodegenerative and ophthalmological diseases are developed.
|
Detailed competitors of TearSolutions
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Tearsolutions
Complete news archive for TearSolutions
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about TearSolutions
TearSolutions was founded in 2013 and raised its 1st funding round 1 year after it was founded.
TearSolutions is headquartered in Charlottesville, United States. It is registered at Charlottesville, Virginia, United States.
TearSolutions is a funded company, having raised a total of $44.07M across 12 funding rounds to date.
TearSolutions develop topical therapeutics for the treatment of dry eye disease. Its lead product is a proprietary synthetic fragment of the protein lacritin. The company claims that Lacripep is equipotent with natural lacritin and can alleviate dry-eye symptoms for up to 16 hours. Its currently in phase I clinical trials.
TearSolutions's top competitors include Remegen, Lineage Cell Therapeutics and Oyster Point Pharmaceuticals.
TearSolutions offers Lacripep.
TearSolutions has 5 investors. Key investors include Santen Pharmaceuticals, VTC Innovation Fund, Pharmstandard, LaunchCapital, and Center for Innovative Technology.